HOUSTON, August 28, 2025 — Leads & Copy — Moleculin Biotech, Inc. (Nasdaq: MBRX) has entered into agreements with certain warrant holders for the immediate exercise of outstanding warrants to purchase up to 16,216,216 shares of common stock, originally issued in June 2025, at $0.37 per share.
The exercise is expected to generate approximately $6.0 million in gross proceeds before financial advisory fees. Roth Capital Partners is the financial advisor for the transaction.
In exchange for the immediate exercise, Moleculin Biotech will issue new unregistered warrants to purchase up to 64,864,864 shares of common stock at an exercise price of $0.55 per share, exercisable upon shareholder approval and for a term of five years.
The transaction is expected to close on August 28, 2025, pending customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes.
The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933. Moleculin Biotech has agreed to file a registration statement with the SEC covering the resale of shares issuable upon exercise of the new warrants.
Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
Source: Moleculin Biotech, Inc.
